Drug Development Time Is Five Years From Target To NDA, Glaxo's Sykes Says
Glaxo SmithKline's development timeline from discovery of a novel target to NDA filing would be as little as five years, Glaxo Wellcome Chairman Richard Sykes maintained during a Jan. 18 briefing on the Glaxo SmithKline merger in New York City.
You may also be interested in...
The Glaxo SmithKline merger will provide an opportunity for antitrust regulators to weigh in on the commercial exploitation of the human genome.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials